Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Enovis Corp received an amended Schedule 13G/A from The Vanguard Group reporting 0 shares beneficially owned, representing 0% of Common Stock as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, under which certain Vanguard subsidiaries report holdings separately.
The filing lists the filer address and certifies no sole or shared voting or dispositive power over Enovis shares. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Enovis Corp’s Chief Administrative Officer, Oliver Engert, made an open-market purchase of company stock. On March 13, 2026, he bought 1,000 shares of Enovis common stock at $23.74 per share. After this transaction, he directly owns 48,640 shares of Enovis common stock.
This was a straightforward open-market buy, increasing his direct equity stake by a relatively small amount compared with his existing holdings.
Enovis CORP Chief Administrative Officer Oliver Engert bought 1,000 shares of common stock in an open-market purchase at a weighted average price of $23.93 per share. This increases his directly owned stake to 47,640 common shares.
The filing notes the purchase was executed through multiple trades within a price range from $23.75 to $24.10 per share. The transaction represents a relatively small addition compared with his total reported holdings, suggesting a routine increase in personal investment exposure to the company.
Enovis Corp’s principal accounting officer John Kleckner received an equity grant of 14,925 shares of common stock on March 9, 2026. The shares were awarded at no cost as restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date.
On March 7, 2026, 586 shares were withheld at $24.51 per share to cover tax obligations tied to a restricted stock unit net settlement, which the company notes is not a sale by Kleckner. Following these transactions, he directly holds 25,884 common shares.
Enovis Corp executive Terry D. Ross, Group President, P&R, received a grant of 36,247 shares of common stock in the form of restricted stock units. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
On a related date, 2,376 shares were withheld by the company at $24.5100 per share to cover tax withholding and remittance obligations tied to the net settlement of RSUs; this did not represent an open-market sale. After these transactions, Ross directly holds 68,477 shares of Enovis common stock.
Enovis senior vice president and chief HR officer Patricia A. Lang received a grant of 25,586 restricted stock units of common stock on March 9, 2026 at no cash cost. The award vests in three equal annual installments beginning on the first anniversary of the grant date.
On March 7, 2026, 2,969 shares were withheld at $24.51 per share to cover tax obligations from restricted stock unit settlement, which the company states does not represent a sale by Lang. Following these transactions, she directly holds 75,703 shares of Enovis common stock.
Enovis CORP Group President, Recon Louis Vogt received an equity award and had shares withheld for taxes. On March 9, 2026, he acquired 36,247 shares of common stock at $0.00 per share as a grant of restricted stock units, bringing his direct holdings to 68,875 shares. On March 7, 2026, 1,980 shares were disposed of at $24.51 per share to cover tax withholding obligations connected to a net settlement of restricted stock units, leaving 32,628 shares following that tax event. A footnote clarifies the 1,980-share disposition was solely to satisfy tax withholding and remittance requirements and does not represent a sale by Vogt. Another footnote states the new restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date.
Enovis CORP senior vice president and chief legal officer Tandy Bradley J received a grant of 25,586 shares of common stock on March 9, 2026 as a compensation award. The award consists of restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date. On March 7, 2026, 1,874 shares were withheld by the company at $24.51 per share to satisfy tax withholding and remittance obligations related to net settlement of restricted stock units, and this did not represent an open-market sale. Following these transactions, Bradley directly holds 65,641 shares of Enovis common stock.
Enovis CORP senior vice president and CFO Phillip Benjamin (Ben) Berry received an equity grant of 47,974 shares of common stock through restricted stock units. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date, aligning his compensation with long-term company performance.
In a separate transaction, 3,167 shares were withheld by the company at a price of $24.51 per share to cover tax obligations tied to the net settlement of restricted stock units, which the company states does not represent a sale by Berry. Following these transactions, he holds 158,596 shares of Enovis common stock directly.
McDonald Damien reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp Chief Executive Officer Damien McDonald received an equity award of 143,923 shares of common stock as a grant at no cash cost on the date of grant. This award consists of restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date. Following this grant, McDonald directly holds 246,676 shares of Enovis common stock.